Skip to main content
SGMOQ logo

SGMOQ · Sangamo Therapeutics, Inc · Documents

Track SGMOQ — free
$0.11 +0.00 (+0.00%) At close · Nov 18 Play latest call Q1 2026 earnings call transcript
Market Cap
$45.57M
Shares
414.29M
Volume · Nov 18 211.89K Avg daily vol (3M) 1.65M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $39.55M down 31.6% 10-K filed Mar 30, 2026 Quarterly report FY2026 Q1 Revenue $1.44M down 77.6% 10-Q filed May 14, 2026 Latest results Financial results 8-K filed May 14, 2026 Earnings call Q1 2026 earnings call Held May 14, 2026
2026
Oct 27
Current report 8-K Events of Oct 23
Regulation FD disclosure

Sangamo Therapeutics, Inc. filed amended July and August monthly operating reports and a September report for its bankruptcy case; its common stock was delisted effective October 17, 2026.

Read from the first part of this long document
Oct 16
Current report 8-K Events of Oct 14
Regulation FD disclosure

Sangamo Therapeutics filed its monthly operating report for August 2026 in its Chapter 11 case. It reported a net loss of -14,449,029 (cumulative -29,369,386), cash receipts of 10,145,433, disbursements of 3,826,691, and an ending cash balance of 23,225,696.

Read from the first part of this long document
Aug 13
Current report 8-K Events of Aug 12
Other events AI summary on its way
Jun 23
Current report 8-K/A Events of Jun 18
Current report AI summary on its way
May 14
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.44M ▼ 77.6% Net loss $31M Diluted EPS -$0.08
Mar 30
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $39.55M ▼ 31.6% Net loss $122.93M Diluted EPS -$0.44
Feb 3
Current report 8-K
Other events AI summary on its way
2025
Mar 17
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $57.8M ▼ 67.2% Net loss $97.94M Diluted EPS -$0.49
2024
Showing 1–50 of 161 documents
Key facts CIK 1001233 CUSIP 800677106 13F (30d) 21 filings 4 filers Visit website Investor relations